However, CIDCA 8348 reduced TNFα, IL-6, and IL-13 secretion while boosting IL-10 and regulatory T cells in IBD patient-derived cells—changes consistent with redox-sensitive immunoregulation (Curciarello et al., 2021). Here, IL6 is linked to inflammatory bowel disease.